| Id: | acc0213 |
| Group: | 2sens |
| Protein: | Tyk2 |
| Gene Symbol: | TYK2 |
| Protein Id: | P29597 |
| Protein Name: | TYK2_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr1054 |
| Site Sequence: | AKAVPEGHEYYRVREDGDSPV |
| Disease Category: | Cancer |
| Disease: | Medulloblastoma |
| Disease Subtype: | |
| Disease Cellline: | TE671 |
| Disease Info: | |
| Drug: | ISG15 OV |
| Drug Info: | "Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, used in the treatment of various cancers including melanoma, non-small cell lung cancer, and classical Hodgkin lymphoma. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations, such as BRCA1/2." |
| Effect: | modulate |
| Effect Info: | "Overexpression of ISG15 reduced the phosphorylation levels of JAK1 (Tyr701), Tyk2 (Tyr1054/1055), STAT2 (Tyr690), and STAT5 (Tyr694) in JEV-infected cells." |
| Note: | Non-conventional drugs |
| Score: | 3.0 |
| Pubmed(PMID): | 20035788 |
| Sentence Index: | 20035788_4-5 |
| Sentence: | "ISG15 over-expression in human medulloblastoma cells significantly reduced the JEV-induced cytopathic effect and inhibited JEV replication by reducing the viral titers and genomes (p<0.05, Student's t-test); it also increased activation of the interferon stimulatory response element (ISRE)-luciferase cis-acting reporter in JEV-infected cells (p<0.05, Chi-square test). Furthermore, Western blotting revealed that ISG15 over-expression increased phosphorylation of IRF-3 (Ser396), JAK2 (Tyr1007/1008) and STAT1 (Tyr701 and Ser727) in JEV-infected cells (P<0.05, Chi-square test)." |
Sequence & Structure:
MPLRHWGMARGSKPVGDGAQPMAAMGGLKVLLHWAGPGGGEPWVTFSESSLTAEEVCIHIAHKVGITPPCFNLFALFDAQAQVWLPPNHILEIPRDASLMLYFRIRFYFRNWHGMNPREPAVYRCGPPGTEASSDQTAQGMQLLDPASFEYLFEQGKHEFVNDVASLWELSTEEEIHHFKNESLGMAFLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVFRRFLRDFQPGRLSQQMVMVKYLATLERLAPRFGTERVPVCHLRLLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIQWWPVEEEVNKEEGSSGSSGRNPQASLFGKKAKAHKAVGQPADRPREPLWAYFCDFRDITHVVLKEHCVSIHRQDNKCLELSLPSRAAALSFVSLVDGYFRLTADSSHYLCHEVAPPRLVMSIRDGIHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQQDGAFVLEGWGRSFPSVRELGAALQGCLLRAGDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEKEHFYQRQHRLPEPSCPQLATLTSQCLTYEPTQRPSFRTILRDLTRLQPHNLADVLTVNPDSPASDPTVFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPQHRSGWKQEIDILRTLYHEHIIKYKGCCEDQGEKSLQLVMEYVPLGSLRDYLPRHSIGLAQLLLFAQQICEGMAYLHAQHYIHRDLAARNVLLDNDRLVKIGDFGLAKAVPEGHEYYRVREDGDSPVFWYAPECLKEYKFYYASDVWSFGVTLYELLTHCDSSQSPPTKFLELIGIAQGQMTVLRLTELLERGERLPRPDKCPCEVYHLMKNCWETEASFRPTFENLIPILKTVHEKYQGQAPSVFSVC
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| TYK2 | FILGOTINIB | Tyrosine-protein kinase TYK2 inhibitor | 4 | - | immune system disease | ATC |
| TYK2 | DEUCRAVACITINIB | Tyrosine-protein kinase TYK2 negative allosteric modulator | 4 | Completed | psoriasis | ClinicalTrials |
| TYK2 | TOFACITINIB CITRATE | Janus Kinase (JAK) inhibitor | 4 | - | rheumatoid arthritis | DailyMed DailyMed |
| TYK2 | DEUCRAVACITINIB | Tyrosine-protein kinase TYK2 negative allosteric modulator | 4 | - | psoriasis | FDA |
| TYK2 | TOFACITINIB CITRATE | Janus Kinase (JAK) inhibitor | 4 | Recruiting | rheumatoid arthritis | ClinicalTrials |
| TYK2 | DEUCRAVACITINIB | Tyrosine-protein kinase TYK2 negative allosteric modulator | 4 | Active, not recruiting | psoriasis | ClinicalTrials ClinicalTrials |
| TYK2 | DEUCRAVACITINIB | Tyrosine-protein kinase TYK2 negative allosteric modulator | 4 | Recruiting | psoriasis | ClinicalTrials |
| TYK2 | FILGOTINIB MALEATE | Tyrosine-protein kinase TYK2 inhibitor | 4 | - | rheumatoid arthritis | EMA |
| TYK2 | UPADACITINIB HEMIHYDRATE | Tyrosine-protein kinase TYK2 inhibitor | 4 | - | rheumatoid arthritis | DailyMed FDA |
| TYK2 | TOFACITINIB CITRATE | Janus Kinase (JAK) inhibitor | 4 | - | psoriatic arthritis | DailyMed |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Active, not recruiting | atopic eczema | ClinicalTrials ClinicalTrials ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Enrolling by invitation | atopic eczema | ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Withdrawn | atopic eczema | ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Completed | atopic eczema | ClinicalTrials ClinicalTrials ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Not yet recruiting | atopic eczema | ClinicalTrials |
| TYK2 | FILGOTINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Completed | Crohn's disease | ClinicalTrials |
| TYK2 | FILGOTINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Terminated | Crohn's disease | ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Active, not recruiting | Crohn's disease | ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Completed | Crohn's disease | ClinicalTrials ClinicalTrials |
| TYK2 | BREPOCITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Recruiting | dermatomyositis | ClinicalTrials |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | Not yet recruiting | Crohn's disease | ClinicalTrials ClinicalTrials |
| TYK2 | PEFICITINIB | Janus Kinase (JAK) inhibitor | 3 | - | immune system disease | ATC |
| TYK2 | UPADACITINIB | Tyrosine-protein kinase TYK2 inhibitor | 3 | - | immune system disease | ATC |
| TYK2 | TOFACITINIB | Janus Kinase (JAK) inhibitor | 3 | Recruiting | glioblastoma multiforme | ClinicalTrials |
| TYK2 | TOFACITINIB | Janus Kinase (JAK) inhibitor | 3 | - | immune system disease | ATC |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| TYK2-Ser577 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | -0.707 |
| GBM | |
| HNSC | |
| LUAD | 0.707 |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
| TYK2-Ser580 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | 1.133 |
| ccRCC | |
| GBM | -0.759 |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | -0.374 |
| TYK2-Ser613 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | -0.707 |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | 0.707 |
| UCEC | |
| TYK2-Ser884 | |
|---|---|
| Cancer | Intensity |
| BRCA | 1.769 |
| COAD | -0.158 |
| HGSC | |
| ccRCC | -1.063 |
| GBM | -0.297 |
| HNSC | 0.414 |
| LUAD | -0.857 |
| LUSC | -0.732 |
| non_ccRCC | |
| PDAC | -0.478 |
| UCEC | 1.4 |
| TYK2-Tyr292 | |
|---|---|
| Cancer | Intensity |
| BRCA | -1.687 |
| COAD | 0.033 |
| HGSC | 1.38 |
| ccRCC | -0.913 |
| GBM | 1.372 |
| HNSC | -0.671 |
| LUAD | -0.118 |
| LUSC | -0.787 |
| non_ccRCC | 0.152 |
| PDAC | 1.193 |
| UCEC | 0.047 |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
